1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma
Year: 2023
Type: article
Source: Annals of Oncology
Authors: J.S. Weber, W. Haque, S.N. Markovic, A.K.S. Salama, I. Mehmi, R.J. Sullivan, Y.G. Najjar, A.C.J. van Akkooi, A.M. Menzies, G.V. Long, A.M. Taylor, J.B.A.G. Haanen, L. Zijlker, K. Davis, S. Karanth, R. Shah, L. Connolly, D. Norton
Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Mayo Clinic, Duke University, Angeles Clinic and Research Institute, Massachusetts General Hospital, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Melanoma Institute Australia, The Netherlands Cancer Institute, RTI Health Solutions, Novartis (United States), Novartis (Ireland)
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4387811076